Editor, OncLive®
Caroline Seymour is your initial point of contact for the OncLive® podcast, OncLive On Air™. She joined the company in 2018 as an assistant editor, with expertise in video production and print/digital publication. Email: cseymour@onclive.com
UCSF Takes Steps to Stop COVID-19 Spread, Ensure Patient Safety
March 24th 2020Thomas G. Martin, MD, discusses the risk of COVID-19 to patients with cancer and precautionary measures implemented by the the University of California San Francisco Helen Diller Family Comprehensive Cancer Center.
Read More
GnRH Antagonists Lead to Lower Odds of Cardiac Complications in Prostate Cancer
March 19th 2020Eugene B. Cone, MD, discusses the advantages of the study, the need for such research, and the potential to broaden these efforts to more novel agents such as abiraterone acetate, enzalutamide, and immune checkpoint inhibitors.
Read More
Ruxolitinib Combo Shows Potential in Post-MPN AML, But Unmet Need Remains
March 18th 2020Prithviraj Bose, MD, discusses the high unmet need in post-myeloproliferative neoplasms acute myeloid leukemia and the impact of findings from the phase I/II trial on current and future treatment strategies in the space.
Read More
Pembrolizumab Plus Enzalutamide Shows Moderate Activity in mCRPC
March 17th 2020Julie N. Graff, MD, discusses the results of the KEYNOTE-199 trial, the importance of combination strategies in metastatic castration-resistant prostate cancer, and the next phase of research for the combination.
Read More
Optimizing Frontline Therapy With Cost-Savings Considerations in CLL
March 12th 2020Matthew S. Davids, MD, MMSc, discusses data that were presented with novel combinations in chronic lymphocytic leukemia at the 2019 ASH Annual Meeting and the importance of conducting cost-effective analyses.
Read More
Integrating Immunotherapy Into HCC Treatment Paradigm
March 10th 2020Ahmed O. Kaseb, MD, discusses important considerations in the frontline treatment of patients with advanced hepatocellular carcinoma, the potential for targeted therapy in the space, and ongoing research with immunotherapy in earlier stages of disease.
Read More
Novel Regimens Show Continued Improvements in Newly Diagnosed Myeloma
March 9th 2020The frontline treatment of patients with multiple myeloma continues to evolve with novel, multidrug regimens that are leading to higher, deeper, and more durable responses, as well as increased rates of minimal residual disease negativity.
Read More
CYP2D6 Genotype Linked With Suboptimal Outcomes in Breast Cancer
March 4th 2020Patients with breast cancer who are ultrarapid or poor CYP2D6 metabolizers of tamoxifen have a worse prognosis compared with normal metabolizers after receiving a standard dose of the drug, due, in part, to a higher incidence of treatment-related adverse events.
Read More
CRM1 Emerges as a Potential Target in Osteosarcoma in Novel Drug Discovery Model
February 26th 2020Alexander Leandros Lazarides, MD, discusses the need for better drug discovery models in osteosarcoma and provides insight into a new personalized medicine pipeline that has the potential to redefine drug development in the field.
Read More
Research Efforts Poised to Redefine Role of Immunotherapy in mCRC
February 21st 2020Neil H. Segal, MD, PhD, discusses the current role of immunotherapy in colorectal cancer and the work being done to define its role in earlier-line settings and among patients with microsatellite stable disease.
Read More
Homing in on Targeted Treatment Strategies in Breast Cancer
February 20th 2020Neelima Denduluri, MD, sheds light on the use of genomic assays in early-stage HR-positive/HER2-negative breast cancer, as well as the agents that are prolonging survival in patients with metastatic HER2-positive disease.
Read More
Nodal Involvement Impacts Surgical Management of Axilla in Breast Cancer
February 19th 2020Hernan Vargas, MD, FACS, discusses the criteria that are used to determine the appropriate surgical intervention for patients with node-positive breast cancer and shared questions that still need to be addressed in the space.
Read More